Recruiting

Observational Study

Sponsor:

NYU Langone Health

Code:

NCT06004349

Conditions

VEXAS Syndome

Autoinflammatory Disease

Autoimmune Disease

Rheumatic Disease

Eligibility Criteria

Sex: All

Age: 0+

Healthy Volunteers: Accepted

Study Details

Brief summary:

This is an exploratory natural history protocol that will enroll patients with known genetic diseases, such as VEXAS syndrome, or as yet undiagnosed disorders of inflammation with the goal of improving our understanding of disease processes. Blood, saliva, hair, nail, or buccal samples may be collected for genetic analysis, blood samples will be obtained for immunologic and other functional studies, and a small number of subjects may undergo skin biopsy.

Conditions

VEXAS Syndome

Autoinflammatory Disease

Autoimmune Disease

Rheumatic Disease

Study ID

NCT06004349

Start date

Apr 15, 2022

Status verified date

Jul, 2026

Completion date

Apr 5, 2032

Anticipated

Primary completion date

Apr 5, 2032

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 0+

Healthy Volunteers: Accepted

Inclusion Criteria:

In order to be eligible to participate in this study as a subject with known or suspected autoinflammatory disease, an individual must meet all of the following criteria:

  • Stated willingness to participate in study procedures (which at the very least includes providing a mail-in blood or saliva sample for genetic analysis);
  • Regardless of sex assigned at birth, at least one month of age;
  • A medical history that, in the expert opinion of the PI and study team, is consistent with the possibility of autoinflammatory disease or known diagnosis of an autoinflammatory disease, such as VEXAS syndrome; and
  • Ability of the subject, parents (in the case of children), or Legally Authorized Representative to understand and the willingness to sign a written informed consent document.

In order to be eligible to participate in this study as a family member of a subject with known or suspected autoinflammatory disease, an individual must meet all of the following criteria:

  • Stated willingness to participate in study procedures (which at the very least includes providing a mail-in sample for genetic analysis);
  • Regardless of sex assigned at birth, at least one month of age;
  • Relationship, either by blood or marriage, to an individual enrolled or about to be enrolled in the study with known or suspected autoinflammatory disease;
  • Likelihood, in the expert opinion of the PI and study team, that analysis of a sample from the individual would advance genetic or functional analysis of the affected relative's possible autoinflammatory condition; and
  • Ability of the subject, parents (in the case of children), to understand and the willingness to sign a written informed consent document.

In order to be eligible to participate in this study as a healthy volunteer, an individual must meet all of the following criteria:

  • Stated willingness to participate in study procedures for healthy volunteers;
  • Regardless of sex assigned at birth, at least five years old, and not pregnant (by history of a missed menstrual period);
  • Likelihood, in the expert opinion of the PI that a sample from the individual would advance the functional analysis of an autoinflammatory condition under study; and
  • Ability of the subject to understand and the willingness to sign a written informed consent document by a capacity assessment provided by the PI and study team.

Exclusion Criteria:

For any of the three categories of subjects, an individual will be excluded from participation in this study for the following reasons:

Probands: an individual will not be enrolled as a proband if the study team has a low suspicion of having an autoinflammatory disease or a genetic cause for an autoinflammatory disease.

Family Members: an individual will not be enrolled as a family member if the study team believes they may have an autoinflammatory disease, in which case, they will be enrolled as a proband.

Healthy controls: an individual will not be enrolled as a healthy control if they have an autoinflammatory disease, or any condition that may mimic an autoinflammatory disease, such as hematologic malignancy, rheumatologic disease.

Study Design

Enrollment

1500 participants

Anticipated

Interventions and Outcome Measures

Arms

Participants with known or suspected autoinflammatory diseases

Participants with known or suspected autoinflammatory diseases (i.e., Probands)

Family member

Family member, either by blood or marriage, to an individual enrolled or about to be enrolled in the study with known or suspected autoinflammatory disease.

Healthy control

Primary outcome measure

  • Number of newly discovered rare, high penetrance germline variants that cause human inflammatory disease [ Time Frame: Study End (Up to Year 5) ]
  • Number of newly discovered structural genomic variants that cause human inflammatory disease [ Time Frame: Study End (Up to Year 5) ]
  • Number of newly discovered common, low penetrance germline variants that confer susceptibility to human inflammatory disease [ Time Frame: Study End (Up to Year 5) ]
  • Number of newly discovered somatic mutations that give rise to human inflammatory disease [ Time Frame: Study End (Up to Year 5) ]

Central Contacts and Locations

Central contacts

Locations

NYC H+H/Bellevue

Recruiting

New York, New York, United States, 10016

NYU Langone Health

Recruiting

New York, New York, United States, 10016

More Information

Sponsor

NYU Langone Health

Last update posted

Jul 8, 2026

Last verified

Jul, 2026

Keywords

  • VEXAS syndrome (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic)

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by NYU Langone Health on 2026-07-08.